1. Future Therapeutic Targets in Management of Autoimmune Skin Diseases
- Author
-
A. E. Karamova, Kubanov Aa, and Kubanova Aa
- Subjects
medicine.medical_treatment ,Autoimmunity ,medicine.disease_cause ,Skin Diseases ,Desmoglein ,Autoimmune Diseases ,Targeted therapy ,Antigen ,immune system diseases ,Humans ,Immunologic Factors ,Medicine ,Adverse effect ,CD20 ,B-Lymphocytes ,integumentary system ,biology ,business.industry ,General Medicine ,medicine.disease ,Pemphigus ,Immunology ,biology.protein ,Rituximab ,business ,medicine.drug - Abstract
Pemphigus is a severe, potentially fatal bullous skin disease, caused by desmoglein autoantibody production and immune-mediated regulation of T-cells subsets. Conventional therapy including systemic corticosteroids with or without other immunosupressants causes numerous adverse effects and becomes inefficient in refractory patients. In this work, the authors showed a modern view on the pathogenesis ofpemphigus. This article describes the detailed action mechanism of rituximab, a chimeric monoclonal antibody directed against CD20 antigen of B-cells. The authors conduct the results of meta-analyses of rituximab's efficiency in pemphigus patients. Moreover, in this article, the authors consider new promising treatment tions and potential targets for biological therapy of pemphigus diseases.
- Published
- 2015
- Full Text
- View/download PDF